Glial cell line–derived neurotrophic factor / Hoth Therap - LARVOL DELTA

Hoth Therapeutics, Inc…announced the initiation of a U.S. Department of Veterans Affairs (VA)–backed study evaluating the potential of glial cell line–derived neurotrophic factor (GDNF)as a novel therapy for obesity and fatty liver disease (hepatic steatosis). (PRNewswire) - "The program is structured under Aim 1 of the approved Statement of Work (SOW), with key milestones as follows: October 2025 – Initiate high-fat and control diet groups; December 2025 – Begin GDNF and comparator dosing; January 2026 – Collect tissue samples and perform data analysis; Q1 2026– Initial results expected."

Clinical data • New trial • Obesity